FOCUS on Drug Approvals. On June 11th, the FDA approved Taletrectinib (Ibtrozi, Nuvation Bio Inc) for adults with locally advanced or metastatic, ROS1-positive, non-small cell lung […]

Focus on Drug Discovery. Lilly will acquire Scorpion Therapeutics’ PI3Kalpha inhibitor program which includes STX-478, a potentially best-in-class mutant-selective PI3Kα inhibitor currently being evaluated in a […]

FOCUS on New Drug Approvals. Last Friday the FDA granted full approval of Deciphera’s Romvimza™ (Vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) […]

FOCUS on New Drug Approvals. Yesterday the FDA approved SpringWorks Therapeutics‘ Mirdametinib (PD-325901) for the treatment of patients with neurofibromatosis type 1 with symptomatic plexiform neurofibromas […]

Focus on Drug Approvals. This week the FDA approved Ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer. Ensartinib is a potent and specific […]

Drug Approval News: The FDA has approved JNJ’s Rybrevant® (Amivantamab-vmjw plus Lazertinib) as a first line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. Lazertinib […]